AngioDynamics Inc Investor and Technology Day (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Great. Can you hear me okay?

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Great. So I'm going to hit along the 3 MedTech. First, just start out with the Nano. Just can you -- since this is driving the future, what -- give us a ballpark for the 2021, fiscal 2021 revenues for Nano. And then how is that -- what's that mix between capital and disposable, just so we have a good base to build off of?

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Okay. I'm a little slow here. So total NanoKnife was $15 million for the year. And what percentage of that was capital? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JULY 13, 2021 / 1:30PM, ANGO.OQ - AngioDynamics Inc Investor and Technology Day (Virtual)

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Okay. Great. That's very helpful. And then as we look at Auryon, just as you get into that market and that product comes out, today, just atherectomy has very low penetration rate. And given the data you're seeing or at least the features and benefits of the improved safety and outcomes for this technology initially, just curious as to what you're seeing in terms of market share versus market penetration into the procedural opportunity. And kind of where do you see that headed? Scott Centea - AngioDynamics, Inc. - Senior VP & GM of Vascular Interventions and Therapies & Peripheral Artery Disease Yes, it's a great question. I think early on, obviously, this is a pretty well-established market already with some of the 4 big players that came before us in a large market. So initially, it was this market share shift away from those devices over to the Auryon system. And now what we're seeing is based on what you just said, the safety, the efficacy, we're actually seeing more and more physicians looking to treat differently these patients before, again, through less medical management, more intervention or percutaneous intervention with atherectomy allowing them to be able to treat more of these patients with, again, the confidence of having that safe as well as effective procedure.

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Great. And then just on the thrombectomy segment, a technical question. But as you launch the cannulas with the AlphaVac product and the similar features that you see with the AngioVac, are those interchangeable cannulas? Or are they each specifically designed like AlphaVac has its own set of cannulas and AngioVac has its own set?

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Okay. And then just last on pricing. As you look at the market, I mean, that's been a -- it's been a super fast-growing market. And as we see different players come in, how do you think about pricing versus the features and benefits?